These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17922877)

  • 41. Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies.
    Marconi M; Ascione B; Ciarlo L; Vona R; Garofalo T; Sorice M; Gianni AM; Locatelli SL; Carlo-Stella C; Malorni W; Matarrese P
    Cell Death Dis; 2013 Oct; 4(10):e863. PubMed ID: 24136227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis.
    Frenzel LP; Patz M; Pallasch CP; Brinker R; Claasen J; Schulz A; Hallek M; Kashkar H; Wendtner CM
    Br J Haematol; 2011 Jan; 152(2):191-200. PubMed ID: 21091905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TRAIL death receptors and cancer therapeutics.
    Huang Y; Sheikh MS
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway.
    Hao Z; Han X; Sun X; Shen M; Huang J; Li Y; Ozawa T; Pang D; Jin S; Kishi H; Muraguchi A; Jin A
    Biochem Biophys Res Commun; 2016 Jun; 475(2):238-44. PubMed ID: 27208782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tissue distribution of the death ligand TRAIL and its receptors.
    Spierings DC; de Vries EG; Vellenga E; van den Heuvel FA; Koornstra JJ; Wesseling J; Hollema H; de Jong S
    J Histochem Cytochem; 2004 Jun; 52(6):821-31. PubMed ID: 15150291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.
    Dicker F; Kater AP; Fukuda T; Kipps TJ
    Blood; 2005 Apr; 105(8):3193-8. PubMed ID: 15339846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
    Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
    Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
    Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; Walczak H
    J Mol Med (Berl); 2009 Oct; 87(10):995-1007. PubMed ID: 19680616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.
    Bertsch U; Röder C; Kalthoff H; Trauzold A
    Cell Death Dis; 2014 Aug; 5(8):e1390. PubMed ID: 25165876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Translating TRAIL-receptor targeting agents to the clinic.
    den Hollander MW; Gietema JA; de Jong S; Walenkamp AM; Reyners AK; Oldenhuis CN; de Vries EG
    Cancer Lett; 2013 May; 332(2):194-201. PubMed ID: 22531313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells.
    Willms A; Schittek H; Rahn S; Sosna J; Mert U; Adam D; Trauzold A
    PLoS One; 2019; 14(4):e0214847. PubMed ID: 30947287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.
    Tamada T; Shinmi D; Ikeda M; Yonezawa Y; Kataoka S; Kuroki R; Mori E; Motoki K
    Sci Rep; 2015 Dec; 5():17936. PubMed ID: 26672965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
    Strekalova E; Malin D; Good DM; Cryns VL
    Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome.
    Matsumura R; Umemiya K; Kagami M; Tomioka H; Tanabe E; Sugiyama T; Sueishi M; Kayagaki N; Yagita H; Okumura K
    Clin Exp Rheumatol; 2002; 20(6):791-8. PubMed ID: 12508770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting TRAIL agonistic receptors for cancer therapy.
    Carlo-Stella C; Lavazza C; Locatelli A; Viganò L; Gianni AM; Gianni L
    Clin Cancer Res; 2007 Apr; 13(8):2313-7. PubMed ID: 17438088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.